" Vitamin C concentrations < 0.8 mmol/L do not interfere with point-of-care glucose monitoring. Intravenous vitamin C infusion of 25 mg/kg every 6 hours does not interfere with point-of-care glucose monitoring unless the patient has renal impairment, in which case laboratory glucose tests should be used."

"Cardiac surgery using hypothermic ECC challenges the accuracy of the Dexcom G6 CGM although recovery appears to occur thereafter."

"Arterial BG measurements during surgery in patients with DM under general anesthesia using POCT BG meter are in general lower than laboratory measurements, but the ICC and CCC show a clinically acceptable correlation. We conclude that POCT measurements conducted on arterial specimens using the ACI II provide sufficiently accurate results for glucose measurement during surgery under general anesthesia."

"The current extent of hematocrit interference on glucose meter performance is anticipated to cause insulin error by 1-dose category, which is likely associated with low patient risk."

"Displaying a numeric BG reading eliminated potentially life-threating treatment errors caused by confusing range abbreviations. Manufacturers should consider these findings during future research and development of POC glucometers."

Rapid POCT results for blood gases and glucose are vital for treating critically ill patients. Analyzing data from MIM-NRI (2017–2024), this study highlights a significant rise in glucometer use during the COVID-19 pandemic and the integration of 13 critical analyzers via the AQURE system. In early 2024, over 40,000 tests were performed with an accuracy rate of 84–86%, supported by strict daily calibrations. Ultimately, a robust POCT data management system accelerates diagnosis and optimizes hospital resources, making it indispensable for modern emergency care.

"Glucube® is a novel non-invasive system based on NIRS technology for monitoring blood glucose levels. Its promising capabilities support further research."

"Compared to the Accu-Chek Inform II, the Cobas Pulse demonstrated greater resilience to interferences. Cobas Pulse meets strict accuracy standards (±10% for hospital use) with low interference, which makes it suitable for care of critically ill patients. The Cobas Pulse is more dependable for POCT across various clinical situations, supporting its role in critical care."

"Blood glucose meters' measurements [Accu-Chek Inform II, Accu-Chek Performa and OneTouch VerioVue] can be affected by hematocrit, and might provide readings not within an acceptable bias. Medical organizations need to verify or validate before using on patients."

While comparing the Nova StatStrip, ACCU-Chek Inform II, and Freestyle Precision Pro against the Cobas 8000 reference analyzer, this study found the Nova StatStrip to be the most reliable and stable device under interference. In contrast, the ACCU-Chek Inform II and Freestyle Precision Pro demonstrated significant inaccuracies related to hematocrit and galactose levels, making them unsuitable for use in critically ill patients.

"The i-SENS glucometers showed stable and accurate results when leftover arterial blood samples were used. Therefore, POC glucometers could be useful in critical care settings, such as intensive care units, where arterial samples are routinely used."

"The i-SENS glucometers showed stable and accurate results when leftover arterial blood samples were used. Therefore, POC glucometers [BAROzen H Expert plus, CareSens PRO, and CareSens H Beat) and the ACCU-CHEK® Inform II] could be useful in critical care settings, such as intensive care units, where arterial samples are routinely used."

This study confirms that the Dexcom G6 CGM system provides acceptable accuracy and high reliability compared to the Accu-Chek Inform II reference meter during elective abdominal surgery. With a mean ARD of 12.7% and 99.2% of data points falling within Clarke Error Grid zones A and B, the Dexcom G6 is a viable tool for enhancing peri-operative glucose management.

"The agreement between glucose measurements using ACI II and the reference laboratory hexokinase test was clinically acceptable with a percentage error of 10.0% (95% CI 8.0 to 11.9). The use of TIVA may negatively affect the measurement performance of the ACI II."

"The Accu-Chek Inform II POCT glucose meter may be efficiently and safely used in inpatient and outpatient MFs and particularly in pediatric clinics."

"The ACCU-CHEK Inform II system demonstrated clinically acceptable performance against the PCA-HK reference method for blood glucose monitoring in a diverse population of critically ill patients in US care settings."

This study reveals a significant diagnostic discrepancy between the Accu-Chek Inform II point-of-care test and the Cobas c701 laboratory method, with the latter diagnosing GDM in 55% of participants compared to only 25%. Despite being a laboratory method, the Cobas c701 exhibited a 5% bias that exceeded clinical standards, whereas the point-of-care test remained accurate. These findings highlight that analytical inaccuracies in glucose measurement can lead to substantial over-diagnosis, fundamentally impacting the clinical management of gestational diabetes.

"We suggest that capillary fasting and 2 h P-glucose samples analyzed on the Accu-chek Inform II could be used for diagnosis of GDM during pregnancy using corrected cutoffs with acceptable accuracy in an antenatal care setting. Duplicate samples are necessary to maintain adequate precision. It is also worth continuing with OGTT when the fasting samples are within a normal range, since more women will receive a diagnosis of GDM."

"It's important to know what is the laboratory reference glucose in evaluating glucose meters' accuracy. The evaluation of glucometers' accuracy with respect to a reference laboratory may be wrong if tubes containing only NaF are used due to in vitro glycolysis. Only tubes containing citrate mixture permit the correct evaluation of glucose meters' accuracy."

"PFG measured at the bedside with a glucometer closely correlates with the laboratory measurement. Further studies are needed prior to incorporating this test in clinical practice."

"The Accu-Chek Inform II POC blood glucose meters performed well in terms of precision, linearity, and correlation evaluations. Consensus guidelines for the large-scale performance evaluations of POC devices are required."

While the Roche Accu-Chek Inform II demonstrates high clinical safety with 90.3% of results in the "No-risk" zone, it fails to meet the strict ISO compliance target of 94.6%. The observed 81.5% compliance and consistent positive bias indicate that although the device is a reliable tool for real-world clinical decision-making, further technical refinements are necessary to align its analytical precision with international standards.

"High-volume and automated tests have lower unit costs, as is the case with the core laboratory. ABC provides the ability to identify high average cost tests that can benefit from optimizations, such as focusing on automation or outsourcing low-volume tests that can benefit from economies of scale."